AstraZeneca plc (AZN) PT Set at GBX 5,333 by Sanford C. Bernstein
AstraZeneca plc (LON:AZN) received a GBX 5,333 ($65.00) price objective from research analysts at Sanford C. Bernstein in a research report issued on Wednesday. The brokerage presently has a a “neutral” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price objective would indicate a potential upside of 6.62% from the stock’s previous close.
A number of other equities research analysts have also recently weighed in on the company. Societe Generale restated a “buy” rating and set a GBX 7,000 ($85.31) price objective on shares of AstraZeneca plc in a research note on Wednesday, September 14th. Morgan Stanley upped their price objective on AstraZeneca plc from GBX 5,000 ($60.94) to GBX 5,800 ($70.69) and gave the stock an “overweight” rating in a research note on Friday, August 19th. Deutsche Bank AG restated a “buy” rating and set a GBX 5,800 ($70.69) price objective on shares of AstraZeneca plc in a research note on Wednesday, September 28th. Goldman Sachs Group Inc. set a GBX 4,000 ($48.75) price objective on AstraZeneca plc and gave the stock a “sell” rating in a research note on Tuesday, September 6th. Finally, Jefferies Group restated a “buy” rating and set a GBX 5,800 ($70.69) price objective on shares of AstraZeneca plc in a research note on Wednesday, September 21st. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. AstraZeneca plc has an average rating of “Hold” and a consensus price target of GBX 4,966.24 ($60.53).
AstraZeneca plc (LON:AZN) traded down 1.17% during midday trading on Wednesday, hitting GBX 4943.50. The company’s stock had a trading volume of 851,901 shares. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The company’s 50-day moving average is GBX 4,996.12 and its 200 day moving average is GBX 4,492.93. The company’s market cap is GBX 62.54 billion.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.